PET-CT 스캐너 기기 시장 보고서 : 유형별, 슬라이스수별, 동위원소 및 검출기 유형별, 서비스 프로바이더별, 용도별, 지역별(2026-2034년)

The global PET-CT scanner device market size reached USD 2.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.33 % during 2026-2034. The market is experiencing stable growth driven by rising prevalence of cancer due to lifestyle changes and environmental factors, increasing technological innovations that are leading to enhanced imaging quality, efficiency, and patient safety, and the growing geriatric population.

PET-CT SCANNER DEVICE MARKET ANALYSIS:

• Market Growth and Size: The market is witnessing steady growth on account of the improving healthcare infrastructure, along with rising investments in advanced imaging technologies.
• Technological Advancements: Integration of artificial intelligence (AI) algorithms and multimodal imaging capabilities is augmenting diagnostic capabilities and streamlining workflows.
• Industry Applications: PET-CT scanner devices find applications in cardiovascular and neurological disorders.
• Geographical Trends: Asia Pacific leads the market, driven by the rising number of new hospitals, diagnostic centers, and specialty clinics. However, North America is emerging as a fast-growing market due to the increasing awareness among individuals about the benefits of early diagnoses.
• Competitive Landscape: Key players are investing in research and development (R&D) activities to develop innovative PET-CT scanner technologies with improved imaging capabilities, enhanced diagnostic accuracy, and patient comfort.
• Challenges and Opportunities: While the market faces challenges, such as high initial costs, it also encounters opportunities on account of the expanding applications of PET-CT imaging.
• Future Outlook: The future of the PET-CT scanner device market looks promising, with the evolving healthcare needs among individuals. Furthermore, the rising development of compact and portable PET-CT scanners will enable PoC imaging, which is anticipated to bolster the market growth.

PET-CT SCANNER DEVICE MARKET TRENDS:

Rising prevalence of cancer cases

The increasing prevalence of cancer among the masses around the world is propelling the PET-CT scanner device market growth. PET-CT scanners play a pivotal role in cancer diagnosis, staging, and treatment monitoring. Early detection through PET-CT imaging enhances treatment efficacy and patient outcomes, contributing to its widespread adoption. Moreover, healthcare providers are increasingly relying on PET-CT scans for accurate disease characterization and personalized treatment planning. These scans utilize radiopharmaceuticals that are selectively taken up by cancer cells, allowing for the visualization of metabolic activity within tumors. Meanwhile, CT scans provide detailed anatomical images that help precisely locate abnormal metabolic activity detected by PET. The comprehensive information obtained from PET-CT scans aids oncologists in making informed decisions regarding treatment strategies, including surgery, radiation therapy, chemotherapy, and targeted therapies. In addition, PET-CT scans enable prompt initiation of treatment and potentially improve patient outcomes. There is a rise in the need for improved access to advanced diagnostic tools to fight against cancer.

Technological advancements

Innovations in PET-CT scanners assist in enhancing imaging quality, efficiency, and patient safety. Modern PET-CT scanners feature higher spatial resolution that allows for clearer visualization of small lesions and improved accuracy in tumor detection and characterization. This advancement enables earlier diagnosis and more precise treatment planning. Moreover, advanced PET-CT scanners offer shorter scan times that benefit in reducing patient discomfort and enhancing workflow efficiency in healthcare settings. Rapid image acquisition enables clinicians to perform more scans in a time frame, leading to increased patient throughput and improved resource utilization. Furthermore, advancements in PET-CT technology are leading to the development of scanners with lower radiation doses while maintaining diagnostic image quality. These scanners improve safety and reduce the risk of long-term adverse effects associated with repeated imaging studies by minimizing radiation exposure to patients. Apart from this, PET-CT scanners employed with advanced motion correction techniques, such as respiratory gating and motion tracking, ensure sharper and artifact-free images.

Increasing geriatric population

The growing demand for PET-CT scanner devices due to rising geriatric population worldwide is positively influencing the market. Elderly individuals are more susceptible to cancer, Alzheimer's disease, cardiovascular disorders, and other chronic diseases, necessitating advanced devices that detect and monitor diseases accurately. PET-CT scanners enable comprehensive assessment of cardiac function, myocardial perfusion, and viability, aiding in the diagnosis and management of cardiovascular conditions in geriatric patients. Moreover, aging is associated with an increased risk of neurodegenerative disorders. PET-CT imaging provides valuable insights into brain metabolism, amyloid deposition, and neuroreceptor binding that facilitate early diagnosis and disease monitoring in elderly individuals. Apart from this, geriatric patients often have multiple comorbidities, requiring comprehensive diagnostic evaluations. PET-CT scanners offer multimodal imaging capabilities, allowing for simultaneous assessment of multiple organ systems in a single examination. This integrated approach benefits in streamlining diagnostic workflows and enhancing clinical decision-making in managing complex health conditions in the elderly.

PET-CT SCANNER DEVICE INDUSTRY SEGMENTATION:

Breakup by Type:

• Stationary Scanners
• Portable Scanners/Mobile Scanners

Stationary scanners account for the majority of the market share

Stationary scanners are large and fixed imaging systems that are usually found in hospitals, imaging centers, and academic institutions. They are designed to provide high-resolution imaging for a wide range of applications, including oncology, cardiology, and neurology. They offer superior image quality and diagnostic accuracy. They have comprehensive anatomical and functional imaging capabilities.

Portable scanners/mobile scanners are compact and mobile imaging systems designed for flexible deployment in various clinical settings, including intensive care units (ICUs), operating rooms, and remote locations. They offer on-site imaging capabilities, enabling POC diagnostics and intraoperative imaging during surgical procedures. They are compact and have a lightweight design for easy transportation.

Breakup by Slice Count:

• Low Slice Scanner (<64 Slices)
• Medium Slice Scanner (64 Slices)
• High Slice Scanner (>64 Slices)

Medium slice scanner (64 slices) holds the largest market share

Medium slice scanner (64 slices) offers enhanced imaging capabilities as compared to low slice scanners and provide higher image resolution, faster scan times, and improved diagnostic accuracy. It is commonly used in larger hospitals, imaging centers, and academic institutions for a wide range of clinical applications. It is suitable for precise tumor localization, staging, and treatment planning. It assists in providing improved image quality and diagnostic accuracy.

Low slice scanner (<64 slices) is suitable for basic imaging applications and commonly found in smaller healthcare facilities, clinics, and outpatient centers where lower throughput and image quality suffice for routine diagnostic purposes. It has basic imaging capabilities for routine diagnostic studies. It is economical and has a space-efficient design suitable for smaller healthcare settings.

High slice scanner (>64 slices) offers advanced imaging performance with ultra-high spatial resolution, rapid scan speeds, and advanced clinical applications. It is used in advanced medical centers, research institutions, and specialized healthcare facilities for demanding imaging studies. It has advanced imaging capabilities for complex clinical and research applications.

Breakup by Isotope and Detector Type:

• Flurodeoxyglucose (FDG)
• 62Cu ATSM
• 18 F Sodium Fluoride
• FMISO
• Gallium
• Thallium
• Others

Flurodeoxyglucose (FDG) represents the leading market segment

Flurodeoxyglucose (FDG) is commonly used radiotracer in PET imaging. It consists of a glucose molecule labeled with a positron-emitting fluorine-18 (^18F) isotope. FDG is taken up by cells in proportion to their metabolic activity, making it a valuable tool for detecting areas of increased glucose metabolism, such as cancerous tumors. It evaluates brain metabolism and detects various neurodegenerative diseases.

62Cu ATSM is a radiotracer used in PET imaging to assess tissue oxygenation. It selectively accumulates in hypoxic regions of tissues, making it useful for identifying areas of poor oxygenation within tumors. 62Cu ATSM PET imaging has potential applications in oncology for predicting tumor response to therapies and guiding treatment decisions.

18 F sodium fluoride is a radiotracer used in PET imaging for assessing bone metabolism. It binds to hydroxyapatite crystals in bone, reflecting areas of active bone formation or remodeling. 18F sodium fluoride PET imaging is valuable for diagnosing bone metastases, evaluating skeletal abnormalities, and monitoring treatment response in bone-related diseases.

FMISO is a radiotracer used in PET imaging to assess tissue hypoxia. It penetrates cell membranes and becomes trapped in hypoxic cells due to reduced oxygen availability. FMISO PET imaging enables visualization and quantification of tissue hypoxia, which is associated with tumor aggressiveness, resistance to therapy, and poor patient outcomes.

Gallium-based radiotracers, such as Ga-DOTA peptides and Ga-PSMA, are used in PET imaging for various clinical applications. Ga-DOTA peptides target somatostatin receptors and are employed in neuroendocrine tumor imaging, while Ga-PSMA targets prostate-specific membrane antigen and is used in prostate cancer imaging.

Breakup by Service Provider:

• Hospitals
• Diagnostic Centers
• Research Institutes

Hospitals exhibit a clear dominance in the market

Hospitals are healthcare institutions that provide a wide range of medical services, including diagnostic imaging. Hospital-based imaging departments offer comprehensive imaging services to inpatients and outpatients and serve a diverse patient population across various medical specialties and clinical settings. It has multidisciplinary teams of healthcare professionals, including radiologists, oncologists, and nuclear medicine physicians.

Diagnostic centers, also known as imaging centers or medical imaging facilities, specialize in providing diagnostic imaging services to patients referred by healthcare providers. These centers focus on diagnostic imaging and offer a range of imaging modalities, including PET-CT scanners, in outpatient settings. They focus on outpatient care, with no inpatient services provided.

Research institutes are academic or independent organizations dedicated to scientific research and innovation. They have advanced imaging technologies, including PET-CT scanners, to support preclinical and clinical research studies across various disciplines. They focus on scientific research and innovation in specific fields of study.

Breakup by Application:

• Oncology
• Neurology
• Cardiology
• Others

Oncology dominates the market share

In oncology, PET-CT imaging plays a critical role in the diagnosis, staging, treatment planning, and monitoring of various types of cancers. PET-CT scans help oncologists visualize metabolic activity within tumors, assess tumor characteristics, detect metastases, and evaluate treatment response. These scanners are beneficial in diagnosing and staging cancers, including lung cancer, breast cancer, colorectal cancer, and lymphoma. They are beneficial in early detection of tumors and metastases for timely intervention.

In neurology, PET-CT imaging is utilized to evaluate brain metabolism, assess neurodegenerative diseases, detect brain tumors, and investigate neurological disorders. PET-CT scans provide valuable insights into brain function, neurotransmitter activity, and cerebral blood flow, aiding in the diagnosis and management of various neurological conditions.

In cardiology, PET-CT imaging is used to assess myocardial perfusion, viability, and function, and to detect and characterize coronary artery disease and other cardiac abnormalities. PET-CT scans provide detailed anatomical and functional information, enabling cardiologists to diagnose cardiac conditions, evaluate treatment options, and assess prognosis.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Asia Pacific leads the market, accounting for the largest PET-CT scanner device market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share due to the presence of well-established new hospitals, diagnostic centers, and specialty clinics. In addition, the rising prevalence of cancer among individuals in the region is bolstering the market growth.

North America stands as another key region in the market, driven by the increasing awareness among individuals about the benefits of early disease detection. Besides this, North America is a hub for technological innovation in healthcare, with leading manufacturers and research institutions continuously developing advanced PET-CT scanner devices.

Europe maintains a strong presence in the market, with the rising focus on improving patient care. Additionally, stringent regulatory standards ensure the safety and efficacy of PET-CT scanner devices, which is impelling the market growth.

Latin America exhibits the growing potential in the market on account of the improving healthcare infrastructure. In addition, the growing demand for advanced care among patients is offering a positive market outlook.

The Middle East and Africa region is primarily driven by the thriving medical tourism. Furthermore, partnerships between local healthcare providers, international medical device manufacturers, and research institutions are facilitating technology transfer and knowledge sharing relayed to PET-CT scanners.

LEADING KEY PLAYERS IN THE PET-CT SCANNER DEVICE INDUSTRY:

Key players are investing in R&D activities to develop innovative PET-CT scanner technologies with improved imaging capabilities, enhanced diagnostic accuracy, and patient comfort. They are exploring new radiotracers and imaging agents to expand the applications of PET-CT scans in oncology, neurology, cardiology, and other medical specialties. Additionally, they are incorporating advanced technologies to automate image analysis, optimize workflows, and improve diagnostic efficiency. Besides this, major manufacturers are introducing next-generation PET-CT scanner models with advanced features, such as higher image resolution, faster scan times, reduced radiation doses, and enhanced software functionalities. They are also developing compact and mobile PET-CT scanners to improve accessibility and flexibility in various clinical settings, including hospitals, clinics, and remote locations.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Bruker Corporation
• Canon Medical Systems, USA Inc.
• GE HealthCare
• Koninklijke Philips N.V.
• Mediso Ltd.
• MinFound Medical Systems Co., Ltd
• MR Solutions
• Neusoft Medical Systems Co., Ltd
• Shimadzu Corporation
• Siemens Healthcare Private Limited
• United Imaging Healthcare Co., Ltd.
• Yangzhou Kindsway Biotech Co., Ltd

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global PET-CT scanner device market in 2025?

2. What is the expected growth rate of the global PET-CT scanner device market during 2026-2034?

3. What are the key factors driving the global PET-CT scanner device market?

4. What has been the impact of COVID-19 on the global PET-CT scanner device market?

5. What is the breakup of the global PET-CT scanner device market based on the type?

6. What is the breakup of the global PET-CT scanner device market based on the slice count?

7. What is the breakup of the global PET-CT scanner device market based on the isotope and detector type?

8. What is the breakup of the global PET-CT scanner device market based on the service provider?

9. What is the breakup of the global PET-CT scanner device market based on the application?

10. What are the key regions in the global PET-CT scanner device market?

11. Who are the key players/companies in the global PET-CT scanner device market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global PET-CT Scanner Device Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Stationary Scanners
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Portable Scanners/Mobile Scanners
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Slice Count

• 7.1 Low Slice Scanner (<64 Slices)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Medium Slice Scanner (64 Slices)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 High Slice Scanner (>64 Slices)
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Isotope and Detector Type

• 8.1 Flurodeoxyglucose (FDG)
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 62Cu ATSM
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 18 F Sodium Fluoride
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 FMISO
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Gallium
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Thallium
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by Service Provider

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Diagnostic Centers
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Research Institutes
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Application

• 10.1 Oncology
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Neurology
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Cardiology
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Bruker Corporation
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Canon Medical Systems, USA Inc.
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
  • 16.3.3 GE HealthCare
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
    • 16.3.3.4 SWOT Analysis
  • 16.3.4 Koninklijke Philips N.V.
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 Mediso Ltd.
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
  • 16.3.6 MinFound Medical Systems Co., Ltd.
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
    • 16.3.6.4 SWOT Analysis
  • 16.3.7 MR Solutions
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Neusoft Medical Systems Co., Ltd
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis
  • 16.3.9 Shimadzu Corporation
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 Siemens Healthcare Private Limited
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
    • 16.3.10.4 SWOT Analysis
  • 16.3.11 United Imaging Healthcare Co., Ltd.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
  • 16.3.12 Yangzhou Kindsway Biotech Co., Ltd
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio